Aug. 7 at 11:07 PM
$CPIX our view, expressed yeaterday, is that the company and shareholders will be maximally rewarded given company sale upon strong dmd data. Lacking scientific, drug development success/experience, and even dollar resources (despite company's proclamation to the contrary) is reason why selling company post positive dmd data, is wisest course of action. Waiting increases risk. No need to wait. A healthy M and A effort needs to be hired and deployed soon to capture reasonable value. Reasonable value may be 500mm, depending on DMD data, Schlerederma data, and "Cancer opporunity"(company language from August 26 earnings call). Pigs in rhis game are almost inevitably slaughtered.
